Compare UCAR & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCAR | NSRX |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | China | Israel |
| Employees | N/A | 7 |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 32.2M |
| IPO Year | 2022 | N/A |
| Metric | UCAR | NSRX |
|---|---|---|
| Price | $1.35 | $3.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $50.00 | $19.67 |
| AVG Volume (30 Days) | ★ 480.7K | 53.9K |
| Earning Date | 05-15-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $1.98 |
| 52 Week High | $4.98 | $9.99 |
| Indicator | UCAR | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 48.07 |
| Support Level | $1.14 | $2.04 |
| Resistance Level | $1.68 | $3.48 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 22.77 | 32.03 |
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.